INOZYME PHARMA, INC.: net income or loss
Net income or loss for INOZYME PHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All INOZYME PHARMA, INC. financial histories
What this measure means
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-01-01 | 2024-12-31 | -102,024,000 | USD | 2025-03-10 | 10-K · 0000950170-25-035940 |
| 2023-01-01 | 2023-12-31 | -71,169,000 | USD | 2025-03-10 | 10-K · 0000950170-25-035940 |
| 2022-01-01 | 2022-12-31 | -67,061,000 | USD | 2024-03-12 | 10-K · 0000950170-24-029673 |
| 2021-01-01 | 2021-12-31 | -56,624,000 | USD | 2023-03-22 | 10-K · 0000950170-23-009053 |
| 2020-01-01 | 2020-12-31 | -56,424,000 | USD | 2022-03-15 | 10-K · 0000950170-22-003789 |
| 2019-01-01 | 2019-12-31 | -19,724,000 | USD | 2021-03-25 | 10-K · 0001564590-21-015250 |
Related financial histories
- INOZYME PHARMA, INC.: total assets
- INOZYME PHARMA, INC.: total liabilities
- INOZYME PHARMA, INC.: stockholders equity
- INOZYME PHARMA, INC.: cash and cash equivalents
- INOZYME PHARMA, INC.: operating cash flow
- INOZYME PHARMA, INC.: capital expenditure payments
- INOZYME PHARMA, INC.: financing cash flow
- INOZYME PHARMA, INC.: investing cash flow
- INOZYME PHARMA, INC.: retained earnings or deficit
- INOZYME PHARMA, INC.: basic weighted-average shares
- INOZYME PHARMA, INC.: diluted weighted-average shares
- INOZYME PHARMA, INC.: basic earnings per share
- INOZYME PHARMA, INC.: diluted earnings per share
- INOZYME PHARMA, INC.: net property, plant and equipment
- INOZYME PHARMA, INC.: share-based compensation expense
- INOZYME PHARMA, INC.: operating income or loss
- INOZYME PHARMA, INC.: current assets
- INOZYME PHARMA, INC.: current liabilities
- INOZYME PHARMA, INC.: current accounts payable
- INOZYME PHARMA, INC.: operating expenses
- INOZYME PHARMA, INC.: research and development expense
Inspect the source
- Entity
- INOZYME PHARMA, INC. / CIK 0001693011
- Captured
- 2026-09-21T17:24:18.471Z
- SEC response SHA-256
ec861933b706c8ee16a37434a4299f3c5965e69abe27f6e0d7f0933b71d72503
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001693011.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))